Compare BHM & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHM | IOBT |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 57.2M |
| IPO Year | N/A | 2021 |
| Metric | BHM | IOBT |
|---|---|---|
| Price | $10.91 | $0.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $15.00 | $3.50 |
| AVG Volume (30 Days) | 8.6K | ★ 740.1K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,462,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.95 | N/A |
| 52 Week Low | $8.05 | $0.32 |
| 52 Week High | $14.81 | $2.79 |
| Indicator | BHM | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 40.43 |
| Support Level | $8.39 | $0.61 |
| Resistance Level | $12.00 | $0.75 |
| Average True Range (ATR) | 0.83 | 0.07 |
| MACD | 0.32 | -0.01 |
| Stochastic Oscillator | 67.34 | 16.12 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The Company is an externally managed REIT managed and advised by Bluerock Homes Manager, LLC.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.